Development and Validation of a Clinical Predictive Model for Identifying Hypertrophic Cardiomyopathy Patients at Risk for Atrial Fibrillation: The HCM-AF Score

Author:

Carrick Richard T.1ORCID,Maron Martin S.1ORCID,Adler Arnon23ORCID,Wessler Benjamin1ORCID,Hoss Sara23ORCID,Chan Raymond H.2ORCID,Sridharan Aadhavi1ORCID,Huang Dou1ORCID,Cooper Craig1ORCID,Drummond Jennifer1ORCID,Rakowski Harry23ORCID,Maron Barry J.1,Rowin Ethan J.1ORCID

Affiliation:

1. Hypertrophic Cardiomyopathy Institute, Division of Cardiology, Tufts Medical Center, Boston, MA (R.T.C., M.S.M., B.W., A.S., D.H., C.C., J.D., B.J.M., E.J.R.).

2. Department of Cardiology, Peter Munk Cardiac Centre, Toronto General Hospital, Canada (A.A., S.H., R.H.C., H.R.).

3. Department of Medicine, University of Toronto, ON, Canada (A.A., S.H., H.R.).

Abstract

Background: Atrial fibrillation (AF) is the most common sustained arrhythmia in hypertrophic cardiomyopathy (HCM), associated with impaired quality of life, risk for embolic stroke, and unpredictable onset. We sought to create a predictive model to identify risk for AF development in HCM. Methods: A cohort of 1900 patients with HCM followed for newly diagnosed AF in the Tufts HCM center was used for model development. A cohort of 387 patients from Toronto General Hospital was used for external validation. Data in the development cohort generated the HCM-AF score, a point score to predict AF probability at 2 and 5 years: left atrial dimension (+2 points per 6 mm increase), age at clinical evaluation (+3 points per 10-year increase), age at initial HCM diagnosis (−2 points per 10-year increase), and heart failure symptoms (+3 points if symptomatic). Results: The HCM-AF score stratifies risk as low (<1.0%/y; score ≤17), intermediate (1.0-2.0%/y; score 18 to 21), and high risk (>2.0%/y; score ≥22) for AF development for individual patients. Concordance of the HCM-AF score was 0.70 in the development cohort and 0.68 in the external validation cohort. In the development cohort, 17.2% of high-risk patients developed AF (rate 3.4%/y), while only 3.3% of low-risk patients developed AF (rate 0.7%/y) at 5 years ( P <0.001). Similarly, in the external validation cohort, 13.3% of high-risk patients developed AF (rate 2.7%/y), whereas only 1.1% of low-risk patients developed AF (rate 0.2%/y). The HCM-AF score provided greater predictive power for future AF risk than left atrial dimension alone (concordance of 0.58) and outperformed other non–HCM risk models. Conclusions: The HCM-AF score is a novel externally validated predictive tool to identify AF risk in HCM. This score can reliably stratify patients with HCM to risk of newly diagnosed AF and offers the opportunity to inform expectations regarding future clinical course.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Physiology (medical),Cardiology and Cardiovascular Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3